openPR Logo
Press release

Companion Diagnostics Market to Surpass US$ 5.0 Billion by 2024

02-15-2017 02:50 PM CET | Advertising, Media Consulting, Marketing Research

Press release from: MRC

The global companion diagnostics (CDx) market was valued at US$ 1,614.5 million in 2015 and is projected to expand at a CAGR of 12.0% during the forecast period 2016 to 2024

Companion diagnostic (CDx) is a diagnostic tool used to determine the suitability of a drug therapy to the patient. It has become a critical part of targeted cancer therapy that allows for development of personalized therapy can be developed and administered to the patient. Whole blood samples, tissues samples, or buccal samples are collected and tested for diagnosis and identification of targeted disease biomarker. CDx is usually utilized in identifying genetic mutations and the health and treatment approach implications. In July 2016, the U.S. FDA released a draft guideline for development of a therapeutic product accompanying an IVD companion diagnostic. Companion diagnostics include Gleevec (imatinib mesylate) and BCR-ABL LDT and DAKO C-KIT PharmDx, Herceptin (trastuzumab) and DAKO Herceptest; and Nolvaldex (tamoxifen) and laboratory-developed estrogen receptor positive test.

Download Sample Report @ https://marketreportscenter.com/request-sample/508244

Market Dynamics

Companion diagnostics are beneficial for pharmaceutical companies who face challenges with respect to high drug development cost, safety and outcome of clinical trials, and long product approval time. Companion diagnostics lowers development costs, improves time to market and enhances drug safety by enabling rapid identification of target biomarker and the most effective drug therapy. For patients, the technology provides better treatment outcomes and lower morbidity risk. Use of technologies such as PCR, immunohistochemistry, and gene sequencing has enabled accurate diagnosis and determination of targeted cancer therapy. As the CDx tests also aid in revealing the off-target effects of a drug along with identification of a molecular target, CDx have become and indispensable tool for oncologists.

Market Taxonomy

This report segments the global companion diagnostics market on the basis of application, technology, and geography. On the basis of application, the market is categorized into breast cancer, lung cancer, colorectal cancer, gastric cancer, melanoma, and others. On the basis of technology, the market is segmented into immunohistochemistry, real-time PCR, gene sequencing, Fluorescence in situ hybridization (FISH), and others. For comprehensive understanding of market dynamics, the global companion diagnostics market is analyzed across key geographical regions namely North America, Europe, Asia Pacific, Latin America, Africa, and Middle East. Each of these regions is analyzed on basis of market findings across major countries in these regions for a macro-level understanding of the market.

Complete Report Details @ https://marketreportscenter.com/reports/508244/companion-diagnostics-market-global-industry-trends-analysis-and-forecast-2017-2024

Key features of the study:

This report provides in-depth analysis of the companion diagnostics and provides market size (US$ Million) and Cumulative Annual Growth Rate (CAGR (%)) for the forecast period: 2016 - 2024, considering 2015 as the base year

It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by the leading players

It profiles leading players in the global companion diagnostics market based on the following parameters company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies and future plans

Key companies covered as a part of this study include Abbott Laboratories, Inc., Agilent Technologies, Inc., Danaher Corporation, GE Healthcare, Qiagen N.V., Roche Diagnostics, Myriad Genetics, Inc., bioMérieux SA, Illumina, Inc. and Siemens Healthcare

Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, technology upgrades, market expansion, and marketing tactics

The global companion diagnostics market report caters to various stakeholders in this industry, including investors, device manufacturers, distributors and suppliers for companion diagnostics, research and consulting firms, new entrants, and financial analysts

Various strategy matrices used in analyzing the companion diagnostics market would provide stakeholders vital inputs to make strategic decisions accordingly

Detailed Segmentation:

Global Companion Diagnostics Market, By Application:
o Breast Cancer
o Lung Cancer
o Colorectal Cancer
o Gastric Cancer
o Melanoma
o Others

Global Companion Diagnostics Market, By Technology:
o Immunohistochemistry
o Real-time PCR
o Gene Sequencing
o FISH
o Others
..…..Continued
Discount On This Report @ https://marketreportscenter.com/request-discount/507788
For more information, please visit https://marketreportscenter.com

Market Reports Center is an e-commerce platform obliging the needs of knowledge workers, experts, professionals who are subject to market research information for their work, or to make strategic business decisions. Market Reports Center’s team consistently works to update and extend our existing repository of market research reports by partnering with new publishers and adding their studies to our website

Sam Collins

303, Astral Court,

Aundh, Pune,

MH - 411045, India

info@marketreportscenter.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Companion Diagnostics Market to Surpass US$ 5.0 Billion by 2024 here

News-ID: 438476 • Views: 156

More Releases from MRC

Global 3D Metrology Software Market Size, Status and Forecast 2022
This report studies the global 3D Metrology Software market, analyzes and researches the 3D Metrology Software development status and forecast in United States, EU, Japan, China, India and Southeast Asia. View Report @ https://marketreportscenter.com/reports/563930/global-3d-metrology-software-market-size-status-and-forecast-2022 This report focuses on the top players in global market, like Carl Zeiss AG Faro Technologies, Inc. H.S. & S. Inc. Heliotis AG Zebicon A/S Creaform Inc. Mitutoyo Corporation Hexagon AB 3d System Corp Nikon Corporation Ge Measurement & Control Solutions Inc. Gom Mbh Perceptron, Inc. Renishaw Plc 3d Digital Corp. Request Sample @
Global Self Guided Torpedo Market Professional Survey Report 2017
This report studies Self Guided Torpedo in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2012 to 2016, and forecast to 2022. View Our Report @ https://marketreportscenter.com/reports/492893/global-self-guided-torpedo-market-professional-survey-report-2017 This report focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, covering Atlas Elektronik BAE Systems Lockheed Martin Raytheon Saab Bharat Dynamics Limited (BDL) DCNS Honeywell International Leonardo-Finmeccanica Orbital ATK Download PDF
Global High-Altitude Pseudo Satellites (HAPS) Sales Market Report 2017
In this report, the global High-Altitude Pseudo Satellites (HAPS) market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. View Our Report @ https://marketreportscenter.com/reports/563370/global-high-altitude-pseudo-satellites-haps-sales-market-report-2017 Geographically, this report split global into several key Regions, with sales (Units), revenue (Million USD), market share and growth rate of High-Altitude Pseudo Satellites (HAPS) for
Global Hyperspectral Remote Sensing Market Future Demand and Growth Analysis 201 …
the following companies as the key players in the global hyperspectral remote sensing market: Corning, Headwall Photonics, ITRES, Norsk Elektro Optikk, and SPECIM Other Prominent Vendors in the market are: BaySpec, Brimrose, CI Systems, Resonon, Telops, and XIMEA. View Our Report @ https://marketreportscenter.com/reports/562239/global-hyperspectral-remote-sensing-market-2017-2021 Commenting on the report, an analyst from Technavio’s team said: “The latest trend gaining momentum in the market is Availability of narrower bandwidths. In hyperspectral remote sensing, narrow bandwidths allow

All 5 Releases


More Releases for Companion

Companion Animal Drugs - Key Market Statistics
Companion animals are pets kept primarily for company, entertainment, and safety. Owners of companion animals consider them to be family, friends, and confidants. Dogs, cats, birds, rabbits, horses, goats, gerbils, rats, mice, and amphibians, others are considered as companion animals. Read Report Overview - https://www.transparencymarketresearch.com/companion-animal-specialty-drugs-market.html According to the American Society for the Prevention of Cruelty to Animals (ASPCA) defines companion animal to be domesticated or domestically-bred whose emotional, physical, social, and behavioral
Companion Animal Vaccine – Improving The Health Of Companion Animals In A Cost …
The companion animal vaccines market is expected to witness significant growth during the forecast period due to launch of vaccines for companion animals. For instance, in December 2017, Zoetis Inc. announced the launch of Vanguard CIV H3N2/H3N8, the latest vaccine in the company’s canine influenza virus (CIV) portfolio. The new bivalent vaccine helps protect dogs against the two strains of the virus known to be circulating in the U.S. Moreover, the
Companion Diagnostics Market - Easing of Regulatory Policies to Drive Global Dem …
Companion diagnostics include two types of tests namely tests which are developed along with target drugs and the other developed after the commercialization of drugs. Companion diagnostics combined with targeted therapeutics are being seen as a major breakthrough in the personalized medicine field. Companies operating in the companion diagnostics market are seeking an effective growth strategy in the development of this concept drug-diagnostic interaction as the healthcare sector is shifting
Global Companion Diagnostics Market
The Global Companion Diagnostics (CDx) Market was valued at US$ 1,614.5 million in 2015 and is projected to expand at a CAGR of 12.0% during the forecast period (2016–2024), as highlighted in a new report published by Coherent Market Insights. Development of multiple biomarkers and targeted drug therapy is boosting research and development collaboration among the industry players. This is expected to improve the time to market for companion diagnostic (CDx) test
Global Companion Diagnostics – Growth Companion for Personalized Medicine
Companion Diagnostics: Growth Companion for Personalized Medicine Personalized medicine is the new segment in discussion among healthcare experts around the globe. Also, encouragement from the regulatory bodies such as the FDA and EMEA in erms of providing a defined structure for companion diagnostic development is driving research activities in personalized medicine. Diagnosis at molecular level for each individual is of prime importance to identify the target biomarker before deciding the therapy.
Companion diagnostics Market: Companion diagnostic are used to determine patient …
The few companion diagnostics are already available in the market for specific types of cancer and many are already under clinical development. Companion diagnostics test depends on finding a specific biomarker in the patient and hence biomarker presence or absence determines whether or not the patient will respond to the treatment. This test require a biopsied tissue to access the expression of biomarker protein or mutant or aberrant genes. Companion